Shopping Cart
Remove All
Your shopping cart is currently empty
iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1. |
| In vitro | iBFAR2 eliminated USP39 ubiquitination in primary mouse CD8+ T cells, inhibited the interaction between JAK2 and USP39, and thereby prevented the deubiquitination of JAK2. This, in turn, facilitated the binding of JAK2 and STAT1, enhancing the phosphorylation of STAT1. |
| In vivo | The compound iBFAR2 (ip; 1, 5, 10 mg/kg; administered once every 2 days starting from day 7 with 9 mice per group) inhibits the growth of MB49 tumors in a dose-dependent manner. |
| Molecular Weight | 360.33 |
| Formula | C19H15F3N2O2 |
| Cas No. | 353484-02-3 |
| Smiles | FC(F)(F)C1=C(C(C2C=CCC23)=CC=C1)NC3C4=CC=C([N+]([O-])=O)C=C4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.